EVT-103

From Wikipedia, the free encyclopedia
EVT-103
Clinical data
Other namesENS-103
Routes of
administration
By mouth
Drug classNMDA receptor antagonist
Identifiers
CAS Number

EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist.[1] As of November 2017, no recent reports of development for major depressive disorder have been identified.[1] The drug was developed as a follow-up compound to EVT-101.[2] The chemical structure of EVT-103 has not been released.[2]

See also[edit]

References[edit]

  1. ^ a b c "EVT 103". AdisInsight. Springer Nature Switzerland AG.
  2. ^ a b Ruppa KB, King D, Olson RE (2012). "NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments". Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry. Vol. 47. pp. 89–103. doi:10.1016/B978-0-12-396492-2.00007-2. ISBN 9780123964922. ISSN 0065-7743.